Europe’s quick commerce sector is entering a new phase of maturity, with profitability replacing growth-at-all-costs as the defining metric for investors. After years of aggressive expansion, consolidation, and high-profile collapses, the sector’s survivors are now demonstrating that rapid grocery delivery can work as a sustainable business. Berlin-based Flink, one of the last independent quick commerce operators standing in Europe, has secured approximately $100 million in new growth capital at a $900 million valuation. The funding round, led by existing investor Prosus, will strengthen Flink’s financial position and support a targeted expansion across its core markets of Germany and the Netherlands. The company plans to open new fulfilment hubs in selected German regions throughout 2026, applying strict profitability and density criteria to each new location rather than pursuing unchecked geographic expansion. Prosus Leads Round as Investor Confidence Returns to Quick Commerce The round was led by Prosus, the Amsterdam-listed technology investment group and long-standing Flink backer, with participation from Btomorrow Ventures, the corporate venture arm of British American Tobacco. Strategic partner REWE, one of Germany’s largest grocery retailers, also remains closely involved in Flink’s operations through a supply chain partnership that gives the company a significant edge in product sourcing and logistics. The investment brings Flink’s total funding to approximately $1.4 billion. Notably, the $900 million valuation represents a substantial reduction from the company’s peak valuation of $5 billion in May 2022, reflecting the broader market correction that swept through the quick commerce sector as pandemic-era demand normalised and investor sentiment shifted decisively towards unit economics over top-line growth. Yet the fact that Prosus continues to lead funding rounds signals genuine confidence in Flink’s restructured business model. The company confirms it is now operating profitably at EBITDA level, a milestone that few quick commerce operators have achieved. Flink reports an average basket size exceeding €45, suggesting it has successfully moved beyond impulse purchases towards serving regular household grocery needs. Quick Commerce Consolidation Reshapes European Market Flink’s funding arrives against a backdrop of dramatic consolidation in the European quick commerce landscape. Gorillas, once a fierce Berlin-based rival, was absorbed by Turkish competitor Getir in late 2023. Getir itself subsequently imploded under financial pressure and was sold to Uber in February 2026, effectively removing the two most prominent competitors from Flink’s core markets. This consolidation has left Flink as one of the last independent quick commerce operators in Europe, with a dense network of fulfilment hubs across approximately 80 cities in Germany and the Netherlands. The company’s expansion plans target 110 cities by 2027, though management has emphasised that each new hub must meet rigorous profitability thresholds before launch. The broader European quick commerce market continues to grow, with Germany’s segment projected to reach $11.6 billion by 2026. Flink’s disciplined approach to expansion, combined with its REWE supply chain partnership and demonstrated path to profitability, positions the company to capture a meaningful share of this growing market without repeating the overextension that plagued earlier entrants. Flink’s journey from pandemic-era losses of €515 million in 2022 to EBITDA profitability represents one of the more compelling turnaround stories in European tech. Whether the company can sustain this trajectory while expanding into new cities will be the key test in the months ahead. Summary Company Flink Headquarters Berlin, Germany Founded 2021 Round Growth Amount $100M Valuation $900M Lead Investor Prosus Other Investors Btomorrow Ventures Total Funding ~$1.4B Use of Funds Expansion of fulfilment hubs in Germany and the Netherlands

The digital therapeutics market for diabetes management is experiencing rapid growth across Europe, as healthcare systems increasingly recognise the potential of software-based interventions to improve patient outcomes and reduce costs. France, with an estimated 4.2 million people living with diabetes, stands at the forefront of this transformation — and one Montpellier-based startup is positioning itself to lead the charge. DiappyMed, the French medtech company behind the clinically validated insulin dose calculation app EkiYou, has raised €5 million in a seed funding round. The investment was led by Ventech and AFI Ventures, with additional participation from Sofilaro and IRDI Capital Investissement. Alongside the raise, DiappyMed has announced a strategic partnership with pharmaceutical giant Sanofi to accelerate the deployment of its digital therapy across France. Ventech and Sanofi Back Personalised Diabetes Care The seed round marks a significant milestone for DiappyMed, which was founded in January 2021 following research conducted at Montpellier University Hospital by co-founder Omar Diouri. The company’s flagship product, EkiYou, is the first digital therapy application in France to have demonstrated clinically proven improvements in postprandial glycaemia within target range — a critical metric for effective diabetes management. EkiYou works by calculating the appropriate insulin dose for patients based on their meals, physical activity levels, and blood glucose readings. The application effectively replaces the complex mental arithmetic that many insulin-dependent patients must perform daily, reducing dosing errors and improving glycaemic control. DiappyMed also launched EkiYou Carbs in November 2022, a complementary carbohydrate counting tool co-developed with Montpellier University Hospital. The partnership with Sanofi is particularly noteworthy. The collaboration aims to massively deploy EkiYou as the first French digital therapy dedicated to personalised insulin dose calculation for both healthcare professionals and patients living with diabetes. Sanofi’s involvement brings not only commercial reach but also deep expertise in insulin therapy, positioning DiappyMed at the intersection of pharmaceutical and digital health innovation. European Digital Therapeutics Market Gains Momentum DiappyMed’s raise arrives at an opportune moment for the digital therapeutics sector. The global market for digital therapeutics in diabetes management was valued at approximately $1.6 billion in 2023 and is projected to reach $5.3 billion by 2033, according to industry estimates. In Europe, regulatory frameworks are evolving to accommodate digital health solutions, with France’s health insurance system moving towards reimbursement of validated digital therapies. Indeed, a central objective for DiappyMed is to achieve reimbursement from the French national health insurance (Assurance Maladie) in 2026. Securing reimbursement would represent a transformative moment for the company, as it would effectively integrate EkiYou into the standard care pathway for insulin-dependent diabetes patients across France — dramatically expanding its addressable market and providing a template for expansion into other European healthcare systems. The €5 million investment will support DiappyMed’s pursuit of this reimbursement milestone, whilst also funding further clinical development, platform enhancements, and the scaling of its commercial partnership with Sanofi. As European healthcare systems grapple with rising diabetes prevalence and mounting treatment costs, digitally enabled solutions like EkiYou represent a compelling proposition for payers, providers, and patients alike. Summary Company DiappyMed Headquarters Montpellier, France Founded January 2021 Round Seed Amount €5 million Lead Investors Ventech, AFI Ventures Other Investors Sofilaro, IRDI Capital Investissement Strategic Partner Sanofi Use of Funds Health insurance reimbursement, clinical development, Sanofi partnership scaling

Europe’s residential energy landscape is undergoing a fundamental transformation as households seek alternatives to volatile grid prices and fossil fuel dependence. At the heart of this shift lies a persistent technical challenge: how to bridge the seasonal gap between summer solar abundance and winter energy demand. Oslo-based Photoncycle believes it has the answer, and has just secured the capital to prove it at scale. Photoncycle has raised €15 million in a Series A round co-led by NordicNinja and Voima Ventures, with continued participation from existing backers Lifeline Ventures, Eviny Ventures, Luminar Ventures, and Momentum. The funding will support the commercial rollout of the company’s solid-state hydrogen energy storage system in Denmark, followed by expansion into the Netherlands ahead of the country’s planned phase-out of net metering. NordicNinja and Voima Ventures back long-duration energy storage play The investor syndicate reflects a strong Nordic conviction in deep-tech climate solutions. NordicNinja, backed by major Japanese corporates, has increasingly focused on European sustainability infrastructure, whilst Voima Ventures brings deep expertise in science-based ventures from its base in Finland. The participation of all existing investors in the round signals continued confidence in Photoncycle’s technology roadmap. Founded in 2020 by CEO Bjørn Brandtzaeg, a visiting fellow at the Massachusetts Institute of Technology where the company was incubated, Photoncycle has developed a system that converts surplus summer solar electricity into hydrogen via a reversible fuel cell. The hydrogen is then processed into a solid state and stored in an underground unit capable of holding up to 10,000 kilowatt-hours of energy — approximately 20 times the density of a comparable lithium-ion battery system. When energy is needed during winter months, the hydrogen is converted back into electricity through a fuel cell, with recovered heat available for space heating or hot water via a heat pump. The storage material itself costs around $1,500 for 10,000 kWh of capacity, a figure that positions Photoncycle’s technology well below conventional long-duration energy storage alternatives designed for residential applications. Europe’s seasonal energy gap creates a substantial market opportunity The residential storage market remains dominated by lithium-ion batteries, which excel at short-duration cycling but are not economically viable for storing energy across seasons. This leaves a significant gap in the European energy transition, particularly in northern countries where solar generation peaks in summer whilst heating demand surges in winter. Denmark represents Photoncycle’s initial commercial beachhead, and for good reason. The country has some of the highest household energy prices in Europe, and approximately 300,000 homes still rely on gas-based heating systems that are scheduled for phase-out by 2035. Photoncycle reports a growing waiting list of Danish homeowners keen to adopt the technology. The company intends to offer its system under a subscription-based model, in which the seasonal storage unit is installed at the customer’s property and operated as part of an integrated energy solution. The model can incorporate existing solar panels or include new installations, and covers maintenance, system operation, and access to energy trading markets. Looking ahead, Photoncycle’s industrialisation plan is ambitious. An industrial plant is set to go live in 2027 as the first phase of a planned 1.4 terawatt-hour annual manufacturing capacity expansion. At full scale, the facility could provide seasonal storage for an estimated 140,000 homes. After Denmark, the Netherlands is next in line, where the impending end of net metering is expected to drive strong demand for residential storage alternatives. The round positions Photoncycle among a growing cohort of European climate-tech ventures tackling the energy storage challenge beyond lithium-ion, in a market segment that is attracting increasing attention from both institutional investors and policymakers focused on energy sovereignty. Summary Company Photoncycle Headquarters Oslo, Norway Founded 2020 Founder & CEO Bjørn Brandtzaeg Round Series A Amount €15 million Lead investors NordicNinja, Voima Ventures Other investors Lifeline Ventures, Eviny Ventures, Luminar Ventures, Momentum Use of funds Commercial rollout in Denmark and Netherlands; first phase of 1.4 TWh annual manufacturing capacity

The application of AI in clinical trials is rapidly reshaping the pharmaceutical development landscape, as biotech companies and contract research organisations grapple with spiralling data complexity and mounting pressure to accelerate drug approvals. Zurich-based Rivia has secured €13 million in Series A funding to scale its agentic data platform, which aims to transform how clinical trial operations teams manage the vast volumes of data generated during modern drug development programmes. The round, led by European venture capital firm Earlybird through its dedicated health fund, brings Rivia’s total funding to approximately €16 million following a €3 million seed round in 2024. New investor Defiant joined the round alongside returning backers Speedinvest, Amino Collective and Nina Capital. The fresh capital will be deployed to expand Rivia’s teams in Zurich and Boston, and to accelerate the rollout of its suite of embedded AI agents designed to automate clinical trial workflows. Earlybird Health leads investment in agentic AI for clinical trials The Series A was led by Earlybird Health, the healthcare-focused arm of pan-European venture firm Earlybird, which manages a dedicated €173 million health fund backing companies that are transforming patient outcomes through technology. The investment underscores growing investor confidence in AI-powered infrastructure for the life sciences sector, particularly platforms that address the operational bottleneck of clinical data management rather than drug discovery alone. Founded in 2022 by Erik Scalfaro and Tiago Kieliger, Rivia was born from first-hand frustration with the fragmented data landscape in pharmaceutical development. Scalfaro, who spent a decade in the pharma industry, has spoken of clinical operations as a world dominated by manual spreadsheet work — downloading hundreds of Excel files, formatting data, and consolidating information rather than focusing on patient outcomes. Kieliger, previously a cybersecurity engineer for the Swiss defence department, brought deep technical expertise in building secure, scalable data infrastructure. Rivia’s platform serves as what the company calls a reusable intelligence layer for clinical trials. Its data engine integrates thousands of heterogeneous data files in real time, applies trial-specific scientific logic through a proprietary library of reusable configurations, and feeds harmonised data directly into operational review workflows. The company currently supports 40 clinical trials across Europe and the United States, handling data volumes that have grown over 400 per cent in the past decade. From data engine to agentic AI in clinical trial operations On this data foundation, Rivia is now launching a suite of embedded AI agents designed to automate high-impact clinical workflows. The company’s first agent, Spark, converts natural-language queries into publication-grade clinical visualisations instantly, eliminating the manual effort traditionally required to produce trial analytics. Additional agents are being deployed for proactive data quality monitoring and oversight workflows, enabling earlier detection of deviations and intelligent prioritisation of issues across trial sites. The broader market opportunity is substantial. The global AI in clinical trials market is estimated at approximately $1.5 billion in 2026 and is projected to reach $18–20 billion by the end of the next decade, driven by increasing data complexity and regulatory pressure for faster, more efficient trial execution. Rivia’s ambition is to reduce clinical trial costs by up to 50 per cent by replacing manual processes with scalable agentic systems — a proposition that resonates strongly in an industry where the average cost of bringing a new drug to market continues to exceed $2 billion. The strategic decision to build the data infrastructure layer before deploying AI agents is central to Rivia’s thesis. As co-founder Kieliger has noted, AI and agents can deliver significant value for clinical trials, but the limiting factor remains the underlying data infrastructure. By establishing a robust intelligence layer that aggregates data across sources and models the specific scientific logic behind each trial, Rivia has created the foundation upon which its agentic capabilities can operate with precision and reliability. With this latest funding, Rivia is well-positioned to capitalise on the accelerating adoption of AI in clinical trials across Europe and the United States. The combination of a proven data platform, embedded AI agents, and backing from specialist healthcare investors suggests the Zurich-based company is building for long-term impact in a sector where efficiency gains translate directly into faster patient access to life-saving therapies. Summary

The autonomous vehicle sector is undergoing a strategic recalibration across Europe, as investors increasingly back companies focused on controlled industrial environments rather than the complexities of open-road driving. Oxford-based Oxa has emerged as a leading beneficiary of this shift, securing $103 million in the first close of its Series D funding round to expand its autonomous driving software across ports, airports, warehouses and manufacturing facilities. The round, which brings Oxa’s total funding to more than $250 million, was anchored by a $50 million commitment from the UK’s National Wealth Fund — a significant endorsement of the company’s industrial automation strategy. Additional backing came from NVentures, Nvidia’s venture capital arm, alongside existing shareholders BP Ventures, IP Group and Australian pension fund Hostplus. A second and final close of the Series D is expected during the first half of 2026. National Wealth Fund and Nvidia Back Industrial Autonomy Vision The involvement of the UK’s National Wealth Fund, which manages £27.8 billion in assets directed at the country’s clean energy and growth industries, signals growing governmental confidence in autonomous vehicle technology as a pillar of British industrial competitiveness. IP Group, the Oxford-based intellectual property commercialisation company, invested £7.5 million from its own balance sheet and a further £19 million through funds it manages on behalf of Hostplus, bringing its combined beneficial holding in Oxa to 20.3 per cent. Nvidia’s participation through NVentures is particularly strategic, given the chipmaker’s dominant position in the AI computing infrastructure that underpins autonomous driving systems. Oxa has been collaborating with Nvidia to accelerate what it terms Industrial Mobility Automation (IMA) — the automation of repetitive driving tasks that businesses perform millions of times daily across logistics and industrial operations. Gavin Jackson, CEO of Oxa, has described Britain as experiencing a “watershed moment” for AI, arguing that advances in digital infrastructure are laying the groundwork for a new industrial era. The funding will enable Oxa to intensify its focus on commercialising solutions for Industrial Mobility Automation, supercharging the development of its configurable and explainable self-driving software, Oxa Driver, and its development toolchain, Oxa Foundry. European Autonomous Vehicle Market Gains Momentum Oxa’s funding round arrives against a backdrop of accelerating investment in European autonomous vehicle technology. The continent captured approximately 38 per cent of the global autonomous vehicle market in 2024, with the Europe and CIS semi- and fully autonomous vehicle market valued at $15.5 billion and projected to reach $26.8 billion by 2030 at a compound annual growth rate of 9.55 per cent. Founded in 2014 as a spinout from the University of Oxford by robotics professors Paul Newman and Ingmar Posner, Oxa — formerly known as Oxbotica — has deliberately pivoted away from the congested open-road self-driving market towards industrial applications where the technology can deliver immediate commercial value. The company’s full-stack autonomous driving software, Oxa Driver, is both vehicle- and platform-agnostic, with no dependence on external infrastructure such as GPS, making it particularly well suited to the controlled but complex environments found in industrial settings. The company’s existing customer base includes major logistics operators such as DHL, energy giant BP and automotive logistics provider Vantec. The fresh capital will be deployed to deepen these relationships, expand into new industrial verticals and further develop Oxa’s technology stack. The broader trend towards industrial autonomy reflects a pragmatic shift in the autonomous vehicle sector, where companies that once pursued ambitious on-road robotaxi visions are finding faster paths to commercialisation in structured environments with predictable traffic patterns and clear operational boundaries. Summary Company Oxa (formerly Oxbotica) Headquarters Oxford, United Kingdom Founded 2014 Founders Paul Newman, Ingmar Posner CEO Gavin Jackson Round Series D (first close) Amount Raised $103 million Key Investors UK National Wealth Fund, NVentures (Nvidia), BP Ventures, IP Group, Hostplus Total Funding Over $250 million Use of Funds Scaling Industrial Mobility Automation across ports, airports, warehouses, and factories

Equity and dilution are the twin forces that shape every founder’s economic outcome. From the moment a startup issues its first shares to the day it exits, the interplay between giving up equity (to investors, employees, and partners) and building value determines whether founding a company is financially transformative or merely a learning experience. Yet many founders enter fundraising negotiations with only a surface-level understanding of how equity dilution works — and the cumulative cost of that knowledge gap can be millions of euros in lost ownership. This guide explains the mechanics of startup equity and dilution in practical terms: how ownership changes with each funding round, how to model the long-term impact of dilution, and how to make informed decisions that protect founder economics through multiple rounds of financing. What Is Equity in a Startup? Equity represents ownership in a company. When founders incorporate a startup, they issue shares — typically ordinary shares (common stock) — that represent 100% ownership. As the company grows and raises capital, new shares are issued to investors, employees, and other stakeholders, changing the ownership distribution. Startup equity exists in several forms. Ordinary shares (common stock) are held by founders and employees. Preferred shares are issued to investors at each funding round and carry additional rights — liquidation preferences, anti-dilution protection, and governance rights — that ordinary shares do not. Stock options give employees the right to purchase shares at a predetermined price (the exercise or strike price) after they vest. Warrants are similar to options but are typically issued to lenders or strategic partners. The critical distinction is between basic ownership (shares currently issued and outstanding) and fully diluted ownership (all issued shares plus all shares that could be issued through options, warrants, and convertible instruments). Investors always think in fully diluted terms, and founders should too. How Dilution Works Dilution occurs whenever new shares are issued, reducing the percentage ownership of existing shareholders. It is a mathematical certainty of raising external capital — and it is not inherently negative. Dilution in exchange for capital that increases the company’s value is a good trade; dilution on unfavourable terms or without corresponding value creation is destructive. The basic dilution formula is: New Ownership % = Old Ownership % × (Old Shares / New Total Shares). If a founder owns 60% of 10 million shares and a new round issues 2.5 million shares to investors, the founder’s ownership drops to 60% × (10M / 12.5M) = 48%. Dilution happens at multiple points during a startup’s life: when co-founders receive their shares (splitting the initial 100%), when advisers receive equity, when the employee stock option pool (ESOP) is created or expanded, at each funding round when new shares are issued to investors, and when convertible instruments (SAFEs, convertible notes) convert into equity. A Typical Dilution Journey Understanding the cumulative impact of dilution across multiple rounds is essential for long-term planning. A realistic European startup dilution trajectory for a two-founder company might look like this: Incorporation: Two co-founders split 100% ownership (50/50 or 60/40). Combined founder ownership: 100%. Pre-seed / Advisers: 2-5% allocated to early advisers and a small initial ESOP. Founder ownership: 95-98%. Seed round: Investors receive 15-25% of the company. If an ESOP is expanded to 10%, the combined dilution from seed investors and the ESOP reduces founder ownership to approximately 65-75%. Series A: Investors receive 15-25%. The ESOP may be topped up to 12-15%. Post-Series A, founders typically retain 40-55% combined ownership. Series B: Another 10-20% dilution from new investors, plus potential ESOP expansion. Post-Series B, founders typically hold 30-45% combined. Series C and beyond: Continued dilution, though typically at smaller percentages as valuations increase. By the time a company reaches Series C, founders may hold 20-35% combined — which, at a company valued at €200 million or more, represents very significant economic value. The Option Pool Shuffle One of the most impactful — and least understood — dilution events occurs not when investors buy shares, but when the employee option pool is created or expanded. At Series A and beyond, investors typically require that the ESOP be carved out of the pre-money valuation, meaning the dilution falls entirely on existing shareholders (founders and seed investors), not on the new investors. The practical impact is significant. A company with a stated €20 million pre-money valuation that must create a 12% ESOP from the pre-money is effectively giving founders a lower real valuation. The €20 million pre-money includes the ESOP, so the implied value of the existing shares is closer to €17.6 million. Founders who negotiate a larger option pool than they actually need are diluting themselves unnecessarily. The optimal approach is to size the ESOP based on your actual hiring plan for the next 18-24 months. If you can demonstrate that you need a 10% pool rather than a 15% pool (with a detailed hiring plan showing specific roles and equity allocations), you save 5 percentage points of dilution — which at a €20 million valuation represents €1 million in founder value. Anti-Dilution Protection Anti-dilution provisions are investor protections that adjust their ownership if the company raises a future round at a lower valuation (a “down round”). These provisions can significantly amplify dilution for founders in adverse scenarios. Broad-based weighted average is the standard and most founder-friendly form. It adjusts the investor’s conversion price based on the weighted average of the old and new prices, taking into account all outstanding shares. The adjustment is proportional and relatively modest. Narrow-based weighted average uses a smaller denominator (only certain share classes) in the calculation, resulting in a larger adjustment and more dilution for founders. It is less common but still encountered. Full ratchet is the most aggressive form — it adjusts the investor’s conversion price to the exact price of the down round, regardless of the amount raised. This can dramatically increase investor ownership at the expense of founders and employees. Full ratchet provisions should be resisted in all but the most exceptional circumstances. Protecting […]

Runway — the number of months a startup can operate before it runs out of cash — is the most fundamental metric in startup survival. Every strategic decision a founder makes is constrained by runway: when to hire, when to fundraise, whether to pursue growth or efficiency, and when to pivot. Yet many founders track their runway only loosely, relying on back-of-the-envelope calculations that miss critical variables. This guide provides a rigorous framework for calculating, extending, and managing your startup’s runway. Understanding runway is not just about knowing when the money runs out. It is about making better decisions every month — decisions that optimise the balance between growth and survival, between ambition and prudence. How to Calculate Startup Runway The basic runway formula is straightforward: Runway (months) = Cash Balance / Monthly Net Burn Rate. If a company has €1.2 million in the bank and spends a net €100,000 per month more than it earns, it has 12 months of runway. However, the simplicity of this formula masks important nuances. The first is the distinction between gross burn and net burn. Gross burn is the total monthly expenditure — salaries, rent, software, marketing, everything. Net burn subtracts revenue from gross burn. A company with €150,000 in monthly expenses and €50,000 in monthly revenue has a gross burn of €150,000 and a net burn of €100,000. The second nuance is that burn rate is rarely constant. Hiring plans, seasonal revenue patterns, one-off expenses (office moves, conference sponsorships, equipment purchases), and annual payments (insurance, software licenses) all cause the burn rate to fluctuate month to month. A more accurate runway calculation uses a forward-looking cash flow model that projects monthly inflows and outflows for the next 12-24 months, accounting for planned hires, known commitments, and expected revenue growth. The Runway Framework: Red, Amber, Green Experienced operators and investors use a traffic-light framework to assess runway health. The thresholds below are guidelines, not rigid rules, but they reflect the consensus among European VCs and CFOs. Green (18+ months). The company is in a strong position. There is ample time to execute on the current plan, hit milestones, and fundraise from a position of strength. Strategic hiring and growth investments can proceed with confidence. Amber (9-18 months). The company should be actively planning its next fundraise. If the plan is to raise equity, the process should begin when runway hits 12 months — fundraising typically takes 3-6 months, and you want to close with at least 6 months of cash remaining. If the plan is to reach profitability, the path must be clearly mapped with specific milestones. Red (under 9 months). Urgent action is required. If a fundraise is not already in progress, the company should immediately reduce burn rate (hiring freezes, discretionary spending cuts) and explore all capital options — equity, venture debt, bridge loans, or revenue-based financing. Fundraising from a position of desperation leads to unfavourable terms, down rounds, or failure. Building a Cash Flow Model A proper runway model goes beyond the simple division formula. It is a month-by-month projection of all cash inflows and outflows, typically built in a spreadsheet with three scenarios: base case, optimistic case, and conservative case. Revenue projections should be based on current run rate, pipeline, and historical conversion rates — not aspirational targets. For the conservative case, assume flat or modest growth. For the optimistic case, assume your sales targets are met. The base case should be your honest best estimate. Expense projections should include every committed cost: current salaries (including employer taxes and benefits, which in Europe can add 25-45% to the gross salary), rent, software subscriptions, professional services, and planned hires with their expected start dates. Do not forget one-off costs: VAT payments, annual insurance renewals, equipment purchases, and conference or travel budgets. Working capital effects matter for companies with significant accounts receivable or accounts payable. A company that invoices enterprise customers on net-60 terms may show strong revenue on the P&L but experience cash inflows 60-90 days after the sale. The cash flow model must account for this timing gap. Strategies to Extend Runway When runway is shorter than desired, founders have several levers to extend it — each with different trade-offs. Reduce burn rate. The most direct approach. Common measures include slowing or freezing hiring, renegotiating vendor contracts, reducing discretionary spending (travel, events, marketing experiments), and in severe cases, salary reductions or layoffs. The key is to cut without destroying the company’s ability to hit the milestones needed for the next round. Accelerate revenue. Offering annual prepayment discounts (pay 12 months upfront for a 15-20% discount), launching a new pricing tier, or focusing sales efforts on quick-close deals can bring cash forward. For SaaS companies, shifting from monthly to annual billing can dramatically improve cash flow. Raise non-dilutive capital. European founders have access to a rich ecosystem of grants, subsidies, and tax incentives that US companies do not. Government innovation grants (Bpifrance, Innovate UK, EIC Accelerator), R&D tax credits (the French CIR, the UK R&D tax relief), and regional development funds can provide meaningful capital with zero dilution. The trade-off is time — grant applications can take months to process. Revenue-based financing. For companies with predictable recurring revenue, revenue-based financing (RBF) provides capital in exchange for a percentage of future revenue until a predetermined amount is repaid. European providers include Capchase, Re:cap, and Uncapped. RBF is non-dilutive and faster than equity fundraising, but the effective cost of capital can be high. Venture debt. As covered in our separate venture debt guide, adding a debt facility alongside or after an equity round can extend runway by 6-12 months with minimal dilution (typically 0.5-2% in warrants). Runway and Fundraising Timing The relationship between runway and fundraising timing is critical. Starting a fundraise too late — with less than 6 months of runway — forces founders into a weak negotiating position. Investors can sense desperation, and they either extract aggressive terms or pass entirely. The optimal time to begin fundraising is when […]

Startup valuation is one of the most debated and least understood aspects of the fundraising process. Unlike mature companies that can be valued based on cash flows, earnings multiples, or asset values, early-stage startups often have minimal revenue, no profits, and uncertain futures. Yet every funding round requires a valuation — a number that determines how much of the company investors receive for their capital and how much founders retain. Understanding the methods, benchmarks, and negotiation dynamics of startup valuation is essential for any founder entering a fundraising process. This guide covers the main valuation methods used at each stage, the benchmarks that European investors apply, and the practical strategies for negotiating a fair valuation that serves both founders and investors. Why Startup Valuation Matters Valuation directly determines dilution — the percentage of the company that founders give up in exchange for capital. A higher valuation means less dilution for the same amount of money raised. However, valuation is not simply “higher is better.” An inflated valuation creates expectations that must be met at the next round; failing to grow into the valuation leads to a down round, which damages morale, triggers anti-dilution provisions, and signals weakness to the market. The optimal valuation is one that fairly reflects the company’s current progress and near-term potential, attracts high-quality investors, and sets a realistic bar for the next funding milestone. Experienced founders and investors refer to this as a “Goldilocks valuation” — not too high, not too low. Valuation Methods for Early-Stage Startups Several methods are used to value startups at different stages. No single method is definitive — in practice, valuations are determined by a combination of methodology, market conditions, and negotiation dynamics. The Berkus Method is one of the simplest frameworks for pre-revenue startups. Developed by angel investor Dave Berkus, it assigns value (up to €500,000 each) to five key risk factors: the quality of the idea, the founding team, the existence of a working prototype, strategic relationships, and evidence of early traction or sales. The maximum pre-money valuation under the Berkus method is €2.5 million, making it suitable for pre-seed and very early seed valuations. Comparable transactions (or “comps”) are the most common method for seed and Series A valuations. This approach looks at what similar companies raised at similar stages and applies those benchmarks. If comparable SaaS companies in Europe are raising Series A rounds at 15-25x ARR, a company with €1 million ARR might expect a pre-money valuation of €15-25 million. The challenge lies in finding truly comparable transactions — sector, geography, growth rate, and market conditions all affect the comparison. Revenue multiples become the dominant method from Series A onward. SaaS companies are typically valued at a multiple of ARR (annual recurring revenue), with the multiple determined by growth rate, retention metrics, gross margins, and market opportunity. High-growth European SaaS companies (100%+ year-over-year growth) might command 20-40x ARR, while steady-growth businesses (30-50% YoY) trade at 8-15x. Marketplace businesses are often valued on a multiple of gross merchandise value (GMV) or net revenue. Discounted cash flow (DCF) analysis is theoretically the most rigorous method but is rarely used for early-stage startups due to the enormous uncertainty in projecting future cash flows. DCF becomes more relevant at growth stage (Series C+) and pre-IPO, where the business model is proven and financial projections are more reliable. Scorecard method adjusts average seed-stage valuations based on specific factors. Starting with the average seed valuation in the relevant market (for example, €4 million in Western Europe), the method applies weighted adjustments for team strength (25% weight), market size (20%), product stage (15%), competitive environment (10%), and other factors. This produces a customised valuation grounded in market averages. European Valuation Benchmarks by Stage While every company is unique, the following ranges represent typical European valuations in 2026. These are medians — outliers exist in both directions. Pre-seed: €1 million – €3 million pre-money. At this stage, valuation is driven almost entirely by team quality, market potential, and the investor’s assessment of risk. Pre-seed valuations vary less by sector and more by geography and investor profile. Seed: €3 million – €8 million pre-money. Companies with a working product and early traction command the higher end. AI, deeptech, and climate startups with strong IP or regulatory moats may exceed this range. Seed valuations have increased by approximately 30% over the past three years across Europe. Series A: €10 million – €30 million pre-money. The range widens significantly at this stage because Series A valuations are anchored to revenue metrics. A SaaS company with €1.5 million ARR growing at 150% annually will command a materially different valuation than one growing at 50%. Series B: €30 million – €100 million pre-money. Growth rate, market position, and path to profitability drive valuations at this stage. The gap between top-quartile and median companies widens considerably. Factors That Drive Valuation Up or Down Beyond the baseline metrics, several factors can significantly influence a startup’s valuation in either direction. Growth rate is the single most powerful driver. A company growing at 3x year-over-year will typically command 2-3x the valuation multiple of a company growing at 1.5x, even with similar absolute revenue. Investors are buying future value, and growth rate is the strongest predictor of future scale. Net revenue retention (NRR) above 120% signals that existing customers are expanding their usage — a strong indicator of product-market fit and a predictor of efficient future growth. Companies with NRR above 130% command premium valuations because each cohort of customers becomes more valuable over time. Competitive dynamics in the fundraise itself matter enormously. A company with three term sheets will achieve a higher valuation than an identical company with one. Creating competitive tension — by running a structured process with multiple interested funds moving in parallel — is the single most effective negotiation lever available to founders. Market conditions fluctuate significantly. In hot markets, valuations rise across the board as more capital chases fewer deals. In downturns, even strong companies may need to […]

Venture debt has emerged as one of the most important complementary financing tools in the European startup ecosystem. Unlike equity funding, which requires founders to sell ownership in their company, venture debt provides capital as a loan — allowing startups to extend their runway, finance specific growth initiatives, or bridge to the next equity round without additional dilution. For venture-backed companies with predictable revenue or clear milestones ahead, venture debt can be a strategically powerful addition to the capital structure. Yet venture debt remains poorly understood by many European founders, who often view it as either a sign of weakness (unable to raise equity) or an unnecessary complication. Neither perception is accurate. Used correctly, venture debt is a tool of financial sophistication — and the European venture debt market has matured significantly, with dedicated providers, standardised terms, and a growing track record of successful deployments. What Is Venture Debt? Venture debt is a form of debt financing specifically designed for venture-capital-backed startups. Unlike traditional bank loans, which require collateral, profitability, and years of financial history, venture debt is underwritten primarily on the strength of the company’s VC backers, its growth trajectory, and its ability to raise future equity rounds. Venture debt typically takes the form of a term loan with a fixed interest rate, a repayment schedule of 24-48 months, and warrants — small equity stakes (typically 0.5-2% of the company) that give the lender upside participation if the company succeeds. The combination of interest payments and warrants makes venture debt more expensive than traditional bank debt but significantly cheaper than equity in terms of dilution. A typical venture debt facility is sized at 25-50% of the most recent equity round. A company that has just raised a €10 million Series A might secure €3-5 million in venture debt alongside or shortly after the equity round. The debt extends the company’s runway by 6-12 months and provides capital for specific initiatives without requiring the founders to raise a larger (and more dilutive) equity round. When to Use Venture Debt Venture debt is most valuable in specific strategic situations. The most common use case is runway extension — adding 6-12 months of operating capital after an equity round to give the company more time to hit milestones before the next raise. This is particularly valuable when the company is close to a significant inflection point (reaching profitability, closing a major contract, or achieving a regulatory milestone) that would meaningfully increase its valuation. Growth financing is another common application. If a company has proven unit economics and needs capital to scale a specific channel (hiring a sales team, expanding into a new market, investing in marketing), venture debt can fund that growth without the months-long distraction of an equity fundraise. This is particularly relevant for SaaS companies with strong net revenue retention, where each incremental customer is clearly accretive. Bridge financing — using debt to bridge between equity rounds when the timing is not ideal — is a valid but riskier use case. If the company is genuinely close to its next fundraise and needs a few months of additional runway, a bridge loan can be appropriate. However, using venture debt to paper over fundamental problems (missed targets, declining growth) is dangerous — it adds a repayment obligation to a company that may already be struggling. Key Terms and Structure Understanding the standard terms of a venture debt facility is essential for evaluating whether a specific offer is competitive. Interest rate. Venture debt typically carries interest rates of 8-14%, depending on the company’s stage, the lender, and market conditions. Rates may be fixed or floating (tied to a benchmark like EURIBOR or SOFR plus a spread). Some facilities include a payment-in-kind (PIK) component, where a portion of the interest accrues rather than being paid in cash — preserving cash flow but increasing the total cost. Warrants. Lenders typically receive warrants to purchase shares equal to 0.5-2% of the company’s fully diluted equity. The warrant strike price is usually set at the price of the most recent equity round. Warrants add dilution, but significantly less than a comparable equity raise would. Covenants. Venture debt agreements include financial covenants — conditions the company must maintain throughout the loan term. Common covenants include minimum cash balance requirements, revenue milestones, and restrictions on additional debt. Breaching a covenant can trigger an event of default, giving the lender the right to accelerate repayment. Draw-down structure. Many venture debt facilities are structured as revolving lines of credit or tranched loans, where the company can draw capital as needed within a specified period (typically 6-12 months). This flexibility means the company only pays interest on capital it actually uses. Venture Debt Providers in Europe The European venture debt market has expanded significantly, with both dedicated venture lenders and traditional financial institutions now actively serving the startup ecosystem. Dedicated venture debt funds include Kreos Capital (one of Europe’s oldest and largest, now part of BlackRock), Bootstrap Europe, Columbia Lake Partners, and Claret Capital Partners. These funds specialise exclusively in lending to VC-backed companies and understand the unique dynamics of startup growth. Public institutions play a uniquely European role. The European Investment Bank (EIB) and its venture debt programme provide large-scale facilities (often €15-50 million) to growth-stage European startups at competitive rates. National development banks — Bpifrance, the British Business Bank, and KfW — also offer venture lending programmes, sometimes on highly favourable terms. Commercial banks have increasingly entered the space. Silicon Valley Bank (now part of First Citizens) maintains a European presence, while HSBC Innovation Banking (formerly SVB UK) and Stifel serve the UK market. European banks like ABN AMRO and ING have also developed startup lending programmes. Risks and Considerations Venture debt is not free money — it carries real risks that founders must understand before signing a facility agreement. The most fundamental risk is the repayment obligation. Unlike equity, which never needs to be repaid, debt must be serviced. If the company’s growth stalls or a subsequent […]

A cap table — short for capitalisation table — is the single most important financial document a startup founder will maintain from day one through to exit. It records who owns what in the company: every share, every option, every convertible instrument, and every vesting schedule. Yet many founders treat their cap table as an afterthought until a Series A investor asks to see it — and discover that years of informal agreements, uncleaned conversions, and poorly tracked option grants have created a mess that takes weeks and thousands in legal fees to untangle. This guide covers everything founders need to know about building, maintaining, and optimising their cap table from incorporation through to growth stage — with particular attention to the European context where multi-jurisdiction structures and local instruments add complexity. What Is a Cap Table? A capitalisation table is a detailed ledger of all equity ownership in a company. At its simplest, it lists every shareholder, the number of shares they own, the class of shares, and their percentage ownership. As the company grows, the cap table expands to include stock options (both vested and unvested), warrants, convertible notes, SAFEs, and any other instruments that could convert into equity. The cap table serves multiple purposes. It is the foundation for fundraising conversations — investors need to understand the existing ownership structure before they can model what their investment will buy. It governs voting rights and governance decisions. It determines how proceeds are distributed in an exit. And it is the basis for tax calculations on equity compensation for employees. A well-maintained cap table should answer several key questions at any moment: who owns what percentage of the company, what is the fully diluted ownership (including all options and convertible instruments), how would a new investment round affect existing shareholders, and how would exit proceeds be distributed at various valuations. Building Your Cap Table From Day One The cap table begins at incorporation. When founders set up the company, they issue the initial shares — typically split among the co-founders according to an agreed ratio. The most common mistake at this stage is not having a frank conversation about equity splits and vesting early. Equal splits among co-founders are simple but not always appropriate; the equity split should reflect each founder’s contribution, commitment, and role. Founder vesting is essential even among co-founders who trust each other implicitly. A standard four-year vesting schedule with a one-year cliff ensures that if a co-founder leaves early, the remaining team retains an appropriate share of the equity. Without vesting, a co-founder who departs after six months could walk away with 33% or 50% of the company — a “dead equity” problem that poisons future fundraising. Share classes. At incorporation, founders typically hold ordinary shares (common stock). When institutional investors come in at seed or Series A, they receive preferred shares — a different class with specific rights (liquidation preferences, anti-dilution protection, governance rights). The cap table must track each class separately, as they carry different economic and governance rights. Initial structure. A clean cap table at incorporation might look like this: 10,000,000 ordinary shares split among 2-3 founders, with a vesting schedule attached to each. Some founders also reserve shares for an early advisor pool (1-3%) and begin setting up an employee stock option plan (ESOP), though the ESOP is often formally created later. How Funding Rounds Affect Your Cap Table Each funding round changes the cap table by issuing new shares to investors, which dilutes existing shareholders proportionally. Understanding this dilution math is critical for founders who want to maintain meaningful ownership through multiple rounds. Pre-money vs post-money valuation. The pre-money valuation is what the company is worth before the new investment. The post-money valuation is the pre-money plus the new capital. If a company has a €10 million pre-money valuation and raises €2.5 million, the post-money is €12.5 million, and the new investors own 20% (€2.5M / €12.5M). All existing shareholders are diluted by 20% — a founder who held 60% now holds 48%. Option pool creation. Series A investors typically require the company to establish or expand an employee stock option pool (ESOP) before the round closes, usually sized at 10-15% of fully diluted shares. Critically, this pool is created from the pre-money valuation — meaning the dilution from the option pool falls on existing shareholders (founders and seed investors), not on the new Series A investors. This is one of the most misunderstood mechanics in startup fundraising and can have a significant impact on effective valuation. Convertible instrument conversion. When SAFEs and convertible notes convert at a priced round, they add additional shares to the cap table. If a company has raised €1 million in SAFEs with a €5 million cap, and the Series A is priced at €10 million pre-money, the SAFEs convert at the €5 million cap — giving SAFE holders a larger percentage than if they had invested at the Series A price. Modelling these conversions accurately before a fundraise is essential to avoid surprises. The Employee Stock Option Pool An employee stock option pool (ESOP) is a reserved block of shares set aside for current and future employees. Options give employees the right to purchase shares at a predetermined price (the “strike price” or “exercise price”) after they vest, typically over four years with a one-year cliff. The ESOP is a critical tool for attracting and retaining talent, particularly in the competitive European tech market where startups cannot always match the salaries offered by large corporations. However, the ESOP also affects the cap table in important ways — every option granted represents potential dilution for all other shareholders. European ESOP structures vary by jurisdiction. In France, the BSPCE (Bons de Souscription de Parts de Créateur d’Entreprise) is a tax-efficient equity incentive scheme specifically designed for startup employees. The UK has EMI (Enterprise Management Incentive) options with favourable tax treatment. Germany has historically been less friendly to employee equity, though recent reforms have improved the […]

Early-stage fundraising rarely begins with a traditional priced equity round. Instead, most pre-seed and seed investments are structured using one of two instruments: SAFE notes (Simple Agreement for Future Equity) or convertible notes. Both allow startups to raise capital quickly without the cost and complexity of a full valuation negotiation — but they work differently, carry different risks, and are better suited to different situations. Understanding these instruments, along with the term sheets that govern later priced rounds, is essential knowledge for any founder raising capital. This guide explains how each instrument works, when to use it, what to negotiate, and how they interact with your cap table — with specific attention to how European practice differs from the US. What Is a SAFE Note? A SAFE (Simple Agreement for Future Equity) is an investment contract created by Y Combinator in 2013 to simplify early-stage fundraising. It is not debt — there is no interest rate, no maturity date, and no repayment obligation. Instead, a SAFE gives the investor the right to receive equity in the company at a future date, typically when the company raises a priced round (such as a Series A). The elegance of the SAFE is its simplicity. The standard Y Combinator SAFE is a five-page document with minimal negotiation points. There are no lawyers’ fees to negotiate complex terms, no board seats, and no ongoing governance obligations. For founders raising a quick pre-seed or seed round, a SAFE is the fastest path from handshake to wire transfer. How SAFEs convert. When the company raises a subsequent priced round (the “qualifying financing”), the SAFE converts into equity — specifically, into the same class of shares issued in that round (typically Series A Preferred). The conversion price is determined by the terms negotiated in the SAFE, usually a valuation cap and/or a discount rate. Valuation cap. The cap sets the maximum valuation at which the SAFE converts. If the SAFE has a €5 million cap and the Series A is priced at €15 million pre-money, the SAFE investor converts at €5 million — giving them significantly more shares per euro invested than the Series A investors. The cap protects early investors from excessive dilution if the company’s valuation increases substantially between the SAFE and the priced round. Discount rate. Some SAFEs include a discount (typically 15-25%) applied to the price of the next round. If the Series A price per share is €10 and the SAFE has a 20% discount, the SAFE converts at €8 per share. Discounts can be used alone or in combination with a cap, in which case the investor gets whichever method produces the lower conversion price. What Is a Convertible Note? A convertible note is a short-term debt instrument that converts into equity at a future financing event. Unlike a SAFE, it is technically a loan — it carries an interest rate (typically 4-8% annually), has a maturity date (usually 18-24 months), and creates a legal obligation for the company to either repay the note or convert it to equity. Convertible notes predate SAFEs by many years and remain widely used globally, particularly in Europe. The conversion mechanics are similar to SAFEs — the note converts at the next priced round, subject to a valuation cap and/or discount. However, the accrued interest on the note also converts, slightly increasing the investor’s ownership. Maturity date implications. If the company has not raised a qualifying round by the maturity date, the note technically becomes due and payable. In practice, most founders and investors negotiate an extension rather than force repayment (which would likely bankrupt an early-stage startup). However, the maturity date gives investors leverage — and savvy investors use it to negotiate additional terms at extension. Interest accrual. While the interest rates on convertible notes are modest (4-8%), the accrued interest converts to equity alongside the principal, slightly increasing the investor’s stake. On a €500,000 note at 6% over 18 months, the investor would convert €545,000 — not a dramatic difference, but it adds up across multiple notes. SAFE vs Convertible Note: When to Use Each The choice between a SAFE and a convertible note depends on jurisdiction, investor preferences, and the specific circumstances of the raise. SAFEs are best suited for very early rounds (pre-seed and early seed) where speed is paramount and the investor base is primarily angels or seed funds familiar with the instrument. SAFEs are standard in the US, increasingly common in the UK and Nordics, and gaining traction across continental Europe. Their simplicity keeps legal costs low (often under €2,000) and allows founders to close individual investors independently over weeks, rather than needing to coordinate a single close. Convertible notes are preferred in many European jurisdictions where the legal framework is better established for debt instruments. Germany, France, Switzerland, and the Benelux countries have well-developed convertible loan structures that local lawyers and investors understand deeply. France has its own variant — the BSA-AIR — which functions similarly to a SAFE but is adapted to French corporate law. Convertible notes are also preferred by investors who want the additional protection of a maturity date and interest accrual. Practical considerations. If your investors are predominantly US-based or from the global angel/accelerator ecosystem, SAFEs are the path of least resistance. If your investors are European funds or local angels, ask what they typically use — forcing an unfamiliar instrument on investors slows the process and increases legal costs. Key Terms to Negotiate Whether using a SAFE or a convertible note, the most important terms to negotiate are the valuation cap and the discount rate. These determine how much of the company early investors will own when the instrument converts. Setting the cap too low gives early investors an outsized stake and can create problems at Series A — incoming investors may demand the cap table be cleaned up, or may reduce their offer to compensate for the existing overhang. Setting the cap too high defeats the purpose of the instrument, as […]

Raising a seed round in Europe has never been more accessible — or more competitive. The continent’s seed ecosystem has expanded dramatically over the past five years, with hundreds of dedicated seed funds, active angel networks, and accelerator programmes creating a dense funding infrastructure that rivals the United States for early-stage founders. Yet the European seed landscape has its own distinct characteristics, and founders who understand its nuances raise faster and on better terms. This guide covers the practical mechanics of raising seed funding in Europe: where the money is, what investors expect, how to structure your round, and the regional differences that shape the European seed experience. Whether you are based in Paris, Berlin, Stockholm, or Tallinn, the fundamentals are consistent — but the local flavour matters. The European Seed Landscape in 2026 Europe’s seed-stage investment activity has matured into a well-functioning market. Median seed round sizes have grown from €500,000 five years ago to approximately €1.5 million to €2.5 million in 2026, with outliers reaching €4 million or more for exceptional teams in hot sectors like AI, defence tech, and climate. The increase reflects both the growing ambition of European founders and the deeper pockets of a new generation of European seed funds. The ecosystem is also more geographically distributed than ever. While London, Paris, and Berlin remain the largest hubs by deal volume, cities like Amsterdam, Stockholm, Copenhagen, Helsinki, Lisbon, Madrid, and Tallinn have each developed thriving seed-stage communities with local investors, incubators, and talent pools. This decentralisation is one of Europe’s strengths — founders can build world-class companies without relocating to a single dominant hub. Types of Seed Investors in Europe Understanding the different types of seed investors — and what each brings beyond capital — is essential for building the right cap table. Dedicated seed funds are the backbone of the European seed ecosystem. These are institutional venture funds that invest exclusively (or primarily) at the seed stage, typically writing initial cheques of €250,000 to €1.5 million. Leading European seed funds include Seedcamp (pan-European), LocalGlobe (London-based, pan-European reach), Point Nine Capital (Berlin, focused on B2B SaaS and marketplaces), Stride VC (London), Kima Ventures (Paris, one of the world’s most active seed investors by volume), and Tiny VC (Nordics). These funds bring pattern recognition, operational support, and — critically — strong networks to help with follow-on fundraising. Angel investors and syndicates play a particularly important role in European seed rounds. Unlike the US, where seed rounds are often led entirely by institutional funds, European seed rounds frequently include a mix of angels and funds. Active angel networks include FJ Labs (global but active in Europe), various national business angel associations, and syndicate platforms such as SeedBlink (strong in CEE and Southern Europe), Leapfunder (Netherlands), and AngelList equivalents in each market. Accelerators and incubators remain important entry points for first-time founders. Y Combinator accepts a growing number of European teams, while Techstars runs programmes across several European cities. European-native programmes like Entrepreneur First (London, Paris, Berlin, Bangalore), Station F (Paris), and Antler (pan-European) provide pre-seed capital (typically €50,000 to €150,000) alongside structured mentorship and investor introductions. Government and public funding is a distinctly European advantage. Bpifrance, the British Business Bank, KfW Capital (Germany), CDTI (Spain), and the European Innovation Council (EIC) all provide grants, loans, or co-investment alongside private capital. Smart founders layer public funding with private investment to reduce dilution and extend runway. What European Seed Investors Expect European seed investors have become more sophisticated and more demanding. The bar has risen from “great idea, strong team” to “great idea, strong team, and early evidence.” The specific expectations vary by sector, but the core requirements are consistent. A working product. Pure idea-stage fundraising is increasingly rare at seed. Most European seed investors expect to see at least an MVP — a functional product that real users or customers have interacted with. For B2B startups, this often means a handful of pilot customers or letters of intent. For consumer products, it means early user data showing engagement and retention. Founder-market fit. Why are you the right team to solve this problem? European investors place high value on domain expertise — founders who have worked in the industry they are disrupting, who understand the regulatory landscape, or who have technical depth that creates a genuine moat. A clear European advantage. Building in Europe is not a disadvantage — it is increasingly a strategy. European founders can leverage strong technical talent pools, lower burn rates than Silicon Valley, proximity to enterprise customers in the world’s largest single market (the EU), and a regulatory environment that increasingly favours European solutions (GDPR, AI Act, data sovereignty). Structuring Your European Seed Round The mechanics of structuring a seed round in Europe differ from the US in several important ways. Instrument choice. While SAFE notes (originated by Y Combinator) have become more common in Europe, convertible notes remain widely used, particularly in continental European jurisdictions where the legal framework is more accommodating to debt instruments. Some jurisdictions also have specific instruments — France has the BSA-AIR (similar to a SAFE), and Germany has convertible loans that are well-established in local practice. For priced rounds, seed-stage term sheets are typically lighter than Series A terms, with simpler governance and fewer investor protections. Valuation expectations. European seed valuations typically range from €3 million to €8 million pre-money, depending on the market, sector, and team track record. AI and deeptech startups with strong IP may command higher valuations. As a rule, European seed valuations are approximately 20-30% lower than comparable US rounds, though this gap has narrowed significantly in recent years. Round composition. A typical European seed round is assembled over 4-8 weeks and might include one institutional seed fund (as lead), one or two additional small funds, and several angels. The lead investor anchors the round with the largest cheque and typically sets the terms, while co-investors fill the remainder. Having a respected lead investor signals quality and makes it significantly easier to close […]